Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with different psychiatric disorders

Neuroscience Letters

Volumn 487, Issue 1, 2011, Pages 99-102

  Emanuele, Enzo ^a   Martinelli, Valentina ^a   Carlin, Maria V ^b   Fugazza, Elisabetta ^a   Barale, Francesco ^a   Politi, Pierluigi ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Centro de Salud Mental   (Spain)

Author keywords

Enzyme linked immunosorbant assay; Major depression; Schizophrenia; Soluble receptor for advanced glycation endproducts

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHOLESTEROL; CREATININE; GLUCOSE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROTHROMBOSIS; BIPOLAR DISORDER; BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; PERSONALITY DISORDER; PILOT STUDY; PRIORITY JOURNAL; SCHIZOPHRENIA; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; CHI-SQUARE DISTRIBUTION; DEPRESSIVE DISORDER, MAJOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PERSONALITY DISORDERS; PILOT PROJECTS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 78650192960     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.10.003     Document Type: Article

References (25)

1. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
2. Bianchi R., Giambanco I., Donato R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol. Aging 2010, 31:665-677.
3. Callaghan R.C., Boire M.D., Lazo R.G., McKenzie K., Cohn T. Schizophrenia and the incidence of cardiovascular morbidity: a population-based longitudinal study in Ontario, Canada. Schizophr. Res. 2009, 115:325-332.
4. Catalano M., Cortelazzo A., Santi R., Contino L., Demicheli M., Yilmaz Y., Zorzetto M., Campo I., Lanati N., Emanuele E. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (receptor for advanced glycation endproducts) and the presence of peripheral arterial disease. Clin. Biochem. 2008, 41:981-985.
5. Chen Y.S., Yan W., Geczy C.L., Brown M.A., Thomas R. Serum levels of soluble receptor for advanced glycation endproducts and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res. Ther. 2009, 11:R39.
6. Clynes R., Moser B., Yan S.F., Ramasamy R., Herold K., Schmidt A.M. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr. Mol. Med. 2007, 7:743-751.
7. Dinan T.G. Inflammatory markers in depression. Curr. Opin. Psychiatry 2009, 22:32-36.
8. Emanuele E., D'Angelo A., Tomaino C., Binetti G., Ghidoni R., Politi P., Bernardi L., Maletta R., Bruni A.C., Geroldi D. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 2005, 62:1734-1736.
9. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., Geroldi D. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1032-1037.
10. Gaens K.H., Ferreira I., van der Kallen C.J., van Greevenbroek M.M., Blaak E.E.E., Feskens J., Dekker J.M., Nijpels G., Heine R.J., 't Hart L.M., de Groot P.G., Stehouwer C.D., Schalkwijk C.G. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J. Clin. Endocrinol. Metab. 2009, 94:5174-5180.
11. Geroldi D., Falcone C., Minoretti P., Emanuele E., Arra M., D'Angelo A. High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J. Am. Geriatr. Soc. 2006, 54:1149-1150.
12. Goldstein B.I., Fagiolini A., Houck P., Kupfer D.J. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar. Disord. 2009, 11:657-662.
13. Hanson D.R., Gottesman I.I. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med. Genet. 2005, 6:7.
14. Hassid B.G., Nair M.N., Ducruet A.F., Otten M.L., Komotar R.J., Pinsky D.J., Schmidt A.M., Yan S.F., Connolly E.S. Neuronal RAGE expression modulates severity of injury following transient focal cerebral ischemia. J. Clin. Neurosci. 2009, 16:302-306.
15. Herold K., Moser B., Chen Y., Zeng S., Yan S.F., Ramasamy R., Emond J., Clynes R., Schmidt A.M. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol. 2007, 82:204-212.
16. Kendler K.S., Gardner C.O., Fiske A., Gatz M. Major depression and coronary artery disease in the Swedish twin registry: phenotypic, genetic, and environmental sources of comorbidity. Arch. Gen. Psychiatry 2009, 66:857-863.
17. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology 2009, 59:123-129.
18. Kim Y.K., Na K.S., Shin K.H., Jung H.Y., Choi S.H., Kim J.B. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1044-1053.
19. Lippi G., Montagnana M., Favaloro E.J., Franchini M. Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin. Thromb. Hemost. 2009, 35:325-336.
20. Santilli F., Vazzana N., Bucciarelli L.G., Davì G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr. Med. Chem. 2009, 16:940-952.
21. Steiner J., Walter M., Wunderlich M.T., Bernstein H.G., Panteli B., Brauner M., Jacobs R., Gos T., Rothermundt M., Bogerts B. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol. Psychiatry 2009, 65:1107-1110.
22. Stewart C., Cha S., Caudle R.M., Berg K., Katz J. Decreased levels of soluble receptor for advanced glycation endproducts in patients with primary Sjogren's syndrome. Rheumatol. Int. 2008, 28(2008):771-776.
23. Vazzana N., Santilli F., Cuccurullo C., Davì G. Soluble forms of RAGE in internal medicine. Intern. Emerg. Med. 2009, 4:389-401.
24. Wittkowski H., Hirono K., Ichida F., Vogl T., Ye F., Yanlin X., Saito K., Uese K., Miyawaki T., Viemann D., Roth J., Foell D. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advanced glycation endproducts and its proinflammatory ligand S100A12. Arthritis. Rheum. 2007, 56(2007):4174-4181.
25. Yang K., Xie G., Zhang Z., Wang C., Li W., Zhou W., Tang Y. Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. Aust. N. Z. J. Psychiatry 2007, 41:266-273.